keyword
MENU ▼
Read by QxMD icon Read
search

Oral ribavirin

keyword
https://www.readbyqxmd.com/read/27917084/sofosbuvir-and-simeprevir-combination-therapy-for-hcv-genotype-1-infection-results-of-a-single-center-va-experience
#1
Seth N Sclair, Maria Del Pilar Hernandez, Evan Vance, Dani Gilinski, Helen Youtseff, Maribel Toro, Marie Antoine, Lennox J Jeffers, Adam Peyton
Treatment of chronic hepatitis C virus (HCV) infection remains a priority in the veterans affairs (VA) health care system nationwide, as there is a high burden of liver disease due to HCV infection among US veterans. The combination of sofosbuvir and simeprevir was the first all-oral antiviral regimen used in clinical practice to treat veterans with HCV infection. In this study, we report a single-center experience showing both the feasibility and effectiveness of this all-oral combination to treat HCV genotype 1 infection...
August 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27910116/the-cost-effectiveness-of-testing-for-ns5a-resistance-associated-polymorphisms-at-baseline-in-genotype-1a-infected-treatment-na%C3%A3-ve-and-treatment-experienced-subjects-treated-with-all-oral-elbasvir-grazoprevir-regimens-in-the-united-states
#2
E H Elbasha, M N Robertson, C Nwankwo
BACKGROUND: The presence of baseline NS5A resistance-associated variants (RAVs) impacted treatment response in HCV genotype 1a (GT1a)-infected patients treated with elbasvir/grazoprevir (EBR/GZR) for 12 weeks, but not patients treated with EBR/GZR and ribavirin (RBV) for 16 weeks. AIM: We assessed the cost-effectiveness of baseline testing for NS5A RAVs in EBR/GZR-treated patients compared without testing and with current treatments for GT1a patients. METHODS: We simulated the course of treatment with EBR/GZR, ledipasvir/sofosbuvir (LDV/SOF) and ombitasvir/paritaprevir/ritonavir+dasabuvir (3D) with or without RBV and natural history of disease of GT1a patients...
December 1, 2016: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27905669/secondary-prophylaxis-of-hepatocellular-carcinoma-the-comparison-of-direct-acting-antivirals-with-pegylated-interferon-and-untreated-cohort
#3
R Vukotic, R Di Donato, F Conti, A Scuteri, C Serra, P Andreone
During the past two decades, several studies showed reduced rates of hepatocellular carcinoma recurrence in patients with HCV-related cirrhosis after interferon-based antiviral therapies respect to untreated controls, even without reaching viral clearance. The recent development of new all-oral regimens with direct-acting antivirals has radically improved the therapeutic management of hepatitis C. Nevertheless, paradoxical, or at least unexpected, high rates of both occurrence and recurrence of hepatocellular carcinoma after a treatment with direct-acting antivirals, have been reported in the recent literature...
December 1, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27857890/prevalence-of-thyroid-disorders-in-hepatitis-c-virus-positive-patients-on-interferon-and-antiviral-therapy
#4
Gitanjali Goyal, Kmds Panag, Ravinder Garg
BACKGROUND: Hepatitis C virus (HCV) infection is common worldwide. The treatment typically involves a combination of interferon-alpha (IFN-α) and ribavirin (RBV) therapy; however, the use of IFN-α is well documented to be associated with thyroid disease, the most common autoimmune disorder associated with IFN-α. AIM: The aim of the present study was to know the prevalence of thyroid abnormality in the HCV-positive patients on IFN and antiviral therapy. MATERIALS AND METHODS: Fifty known HCV positive patients were enrolled for the study...
October 2016: International Journal of Applied and Basic Medical Research
https://www.readbyqxmd.com/read/27845298/daclatasvir-plus-sofosbuvir-with-or-without-ribavirin-in-real-world-patients-with-hiv-hcv-coinfection-and-advanced-liver-disease
#5
Jürgen K Rockstroh, Patrick Ingiliz, Jörg Petersen, Markus Peck-Radosavljevic, Tania M Welzel, Marc Van der Valk, Yue Zhao, Maria Jesus Jimenez Exposito, Stefan Zeuzem
BACKGROUND: HIV/HCV-coinfected patients respond just as well to modern direct-acting antiviral HCV therapy as HCV-monoinfected patients. However, clinical data for all-oral HCV treatments are sparse in HIV/HCV-coinfected patients with an advanced stage of liver cirrhosis. METHODS: A subanalysis of efficacy and safety for a daclatasvir (DCV) and sofosbuvir (SOF) regimen, with or without ribavirin (RBV), was undertaken in HIV/HCV-coinfected patients with advanced liver disease and no other treatment options enrolled into a European DCV compassionate use programme...
November 15, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27827877/acute-hepatitis-e-two-sides-of-the-same-coin
#6
REVIEW
Johannes Hartl, Malte H Wehmeyer, Sven Pischke
The relevance of acute hepatitis E virus (HEV) infections has been underestimated for a long time. In the past, HEV infection had been interpreted falsely as a disease limited to the tropics until the relevance of autochthonous HEV infections in the Western world became overt. Due to increased awareness, the incidence of diagnosed autochthonous HEV infections (predominantly genotype 3) in industrialized countries has risen within the last decade. The main source of infections in industrialized countries seems to be infected swine meat, while infections with the tropical HEV genotypes 1 and 2 usually are mainly transmitted fecal-orally by contaminated drinking water...
November 3, 2016: Viruses
https://www.readbyqxmd.com/read/27815225/boceprevir-plus-pegylated-interferon-ribavirin-to-re-treat-hepatitis-c-virus-genotype-1-in-hiv-hcv-co-infected-patients-final-results-of-the-spanish-boc-hiv-hcv-study
#7
M Laguno, M A Von Wichmann, E Van den Eynde, J Navarro, C Cifuentes, J Murillas, S Veloso, M Martínez-Rebollar, J M Guardiola, A Jou, J L Gómez-Sirvent, M Cervantes, J A Pineda, S López-Calvo, A Carrero, M L Montes, E Deig, A Tapiz, J D Ruiz-Mesa, A Cruceta, E de Lazzari, J Mallolas
INTRODUCTION: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC+pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. METHODS: This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis)...
November 1, 2016: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/27806815/new-direct-acting-antiviral-agents-for-the-treatment-of-hepatitis-c-2016-and-beyond
#8
Muhammad Umar, Tayyab Saeed Akhter
Hepatitis C is one of the commonest public health problems with 130 million people infected worldwide and the burden is increasing. Previously, Interferon along with Ribavirin was the mainstay of treatment but it was associated with toxic side effects. An all-oral regimen with higher rates of sustained viral response (SVR), minimal side effects and no restriction for liver fibrosis staging, was long awaited. Several all-oral interferon-free direct acting antiviral agents (DAAs) have now been approved by FDAfor different genotypes of HCV...
October 2016: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/27804195/the-value-of-cure-associated-with-treating-treatment-na%C3%A3-ve-chronic-hepatitis-c-genotype-1-are-the-new-all-oral-regimens-good-value-to-society
#9
Zobair M Younossi, Haesuk Park, Douglas Dieterich, Sammy Saab, Aijaz Ahmed, Stuart C Gordon
BACKGROUND & AIMS: All-oral regimens are associated with high cure rates in hepatitis C virus-genotype 1 (HCV-GT1) patients. Our aim was to assess the value of cure to the society for treating HCV infection. METHODS: Markov model for HCV-GT1 projected long-term health outcomes, life years, and quality-adjusted life years (QALYs) gained. The model compared second-generation triple (sofosbuvir+pegylated interferon+ribavirin [PR] and simeprevir+PR) and all-oral (ledipasvir/sofosbuvir and ombitasvir+paritaprevir/ritonavir+dasabuvir±ribavirin) therapies with no treatment...
November 2, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27790729/all-oral-direct-acting-antiviral-therapy-in-hcv-advanced-liver-disease-is-effective-in-real-world-practice-observations-through-hcv-target-database
#10
K R Reddy, J K Lim, A Kuo, A M Di Bisceglie, J S Galati, G Morelli, G T Everson, P Y Kwo, R S Brown, M S Sulkowski, L Akuschevich, A S Lok, P J Pockros, M Vainorius, N A Terrault, D R Nelson, M W Fried, M P Manns
BACKGROUND: Chronic hepatitis C virus therapy in patients with advanced liver disease remains a clinical challenge. HCV-TARGET collects data in patients treated at tertiary academic and community centres. AIM: To assess efficacy of all-oral HCV therapy in advanced liver disease. METHODS: Between December 2013 and October 2014, 240 patients with a MELD score of ≥10 initiated HCV treatment with an all-oral regimen. Data from the 220 patients who completed 12-week follow-up were analysed...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27753065/chronic-norovirus-infection-and-common-variable-immunodeficiency
#11
Jeremy Woodward, Effrossyni Gkrania-Klotsas, Dinakantha Kumararatne
Chronic infection with Norovirus is emerging as a significant risk for patients with immunodeficiency - either primary or secondary to therapeutic immunosuppression. Patients with primary immunodeficiency present a range of pathological responses to Norovirus infection. Asymptomatic infections occur and differentiating viral carriage or prolonged viral shedding after self-limiting infection from infection causing protracted diarrhoea can be challenging due to relatively mild pathological changes that may mimic other causes of diarrhoea in such patients (for instance pathogenic bacteria or parasites or graft-versus-host disease)...
October 18, 2016: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/27749571/fatal-systemic-adenoviral-infection-superimposed-on-pulmonary-mucormycosis-in-a-child-with-acute-leukemia-a-case-report
#12
Yu Mi Seo, Seok Hwang-Bo, Seong Koo Kim, Seung Beom Han, Nack-Gyun Chung, Jin Han Kang
BACKGROUND: Although adenovirus (ADV) infection usually causes self-limiting respiratory disorders in immune competent children; severe and systemic ADV infection in children undergoing chemotherapy for leukemia has been continuously reported. Nevertheless, there has been no consensus on risk factors and treatment strategies for severe ADV infection in children undergoing chemotherapy. CASE SUMMARY: We report a case of a 15-year-old boy with a fatal systemic ADV infection...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27748564/the-impact-of-hepatitis-c-virus-outside-the-liver-evidence-from-asia
#13
REVIEW
Zobair M Younossi, Atsushi Tanaka, Yuichiro Eguchi, Young-Suk Lim, Ming-Lung Yu, Norifumi Kawada, Yock Young Dan, Craig Brooks-Rooney, Francesco Negro, Mario U Mondelli
Between 80 and 115 million people worldwide are chronically infected with hepatitis C virus, with 60%-90% of these being undiagnosed. Untreated chronic hepatitis C (CHC) is associated with progressive liver disease, cirrhosis, hepatocellular carcinoma and liver-related mortality. A number of extrahepatic manifestations are also reported in CHC patients, further adding to the burden of the disease. CHC also impacts patients in terms of lower health-related quality of life, higher levels of fatigue and reduced productivity...
October 17, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27741116/assessment-of-cost-of-innovation-versus-the-value-of-health-gains-associated-with-treatment-of-chronic-hepatitis-c-in-the-united-states-the-quality-adjusted-cost-of-care
#14
Zobair M Younossi, Haesuk Park, Douglas Dieterich, Sammy Saab, Aijaz Ahmed, Stuart C Gordon
BACKGROUND: New direct-acting antiviral (DAA) therapy has dramatically increased cure rates for patients infected with hepatitis C virus (HCV), but has also substantially raised treatment costs. AIM: The aim of this analysis was to evaluate the therapeutic benefit and net costs (i.e. efficiency frontier) and the quality-adjusted cost of care associated with the evolution of treatment regimens for patients with HCV genotype 1 in the United States. DESIGN: A decision-analytic Markov model...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27740516/daclatasvir-and-peginterferon-ribavirin-for-black-african-american-and-latino-patients-with-hcv-infection
#15
Maribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, Lennox Jeffers, Steven-Huy Han, Paul J Thuluvath, Vinod Rustgi, Stephen Harrison, Reem Ghalib, John M Vierling, Velimir Luketic, Philippe J Zamor, Natarajan Ravendhran, Timothy R Morgan, Brian Pearlman, Christopher O'Brien, Hicham Khallafi, Nikolaos Pyrsopoulos, George Kong, Fiona McPhee, Philip D Yin, Eric Hughes, Michelle Treitel
:  Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and white non-Latino patients with chronic HCV genotype 1 infection. MATERIAL AND METHODS: In this single-arm, open-label study, 246 patients received daclatasvir plus pegIFN alfa-2a and weight-based RBV. Patients with an extended rapid virologic response (eRVR; undetectable HCV-RNA at treatment weeks 4 and 12) received 24 weeks of treatment; those without eRVR received an additional 24 weeks of treatment with pegIFN alfa-2a/RBV...
November 2016: Annals of Hepatology
https://www.readbyqxmd.com/read/27730529/sofosbuvir-velpatasvir-a-review-in-chronic-hepatitis-c
#16
Sarah L Greig
A once-daily, single-tablet, pangenotypic regimen comprising the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir and the HCV NS5A inhibitor velpatasvir (sofosbuvir/velpatasvir; Epclusa(®)) was recently approved for the treatment of adults with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in the USA, EU and Canada. In the phase III ASTRAL trials, once-daily oral sofosbuvir/velpatasvir for 12 weeks provided very high rates of sustained virological response at 12 weeks post treatment (SVR12) in treatment-naive and -experienced patients with chronic HCV genotype 1-6 infection, including those with compensated cirrhosis or HIV-1 co-infection...
October 11, 2016: Drugs
https://www.readbyqxmd.com/read/27710134/patient-reported-and-economic-outcomes-related-to-sofosbuvir-and-ledipasvir-treatment-for-chronic-hepatitis-c
#17
Linda Henry, Zobair Younossi
We used published literature from 2013- 2016, to review data regarding the new all oral interferon and ribavirin free direct acting antiviral (DAA's) treatment regimens. Areas covered: Specifically, this paper will address DAA's clinical efficacy, their associated patient reported outcomes, their adherence to treatment, and their cost-effectiveness of treatment using studies from the United States. Expert commentary: The current data suggest that cure and elimination of HCV appears to be on the horizon; however, more research is needed to verify similar results from real world practices...
October 6, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27694754/liver-fibrosis-and-body-mass-index-predict-hepatocarcinogenesis-following-eradication-of-hepatitis-c-virus-rna-by-direct-acting-antivirals
#18
Norio Akuta, Masahiro Kobayashi, Fumitaka Suzuki, Hitomi Sezaki, Shunichiro Fujiyama, Yusuke Kawamura, Tetsuya Hosaka, Mariko Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
BACKGROUND AND AIMS: Predictive factors for hepatocarcinogenesis following eradication of hepatitis C virus (HCV) RNA by antiviral therapy with direct-acting antivirals are unknown. Especially the impact of treatment with or without interferon on hepatocarcinogenesis is not clear. METHODS: A total of 958 patients with HCV genotype 1-related chronic liver disease and a sustained virological response defined as negative HCV RNA 24 weeks after cessation of antiviral therapy with direct-acting antivirals (triple therapy of NS3/4A protease inhibitor/peginterferon/ribavirin or all-oral combination therapy with NS3/4A protease inhibitor plus NS5A inhibitor) were included in a retrospective study...
2016: Oncology
https://www.readbyqxmd.com/read/27677786/community-based-real-world-treatment-outcomes-of-sofosbuvir-ledipasvir-in-asians-with-chronic-hepatitis-c-virus-genotype-6-in-the-united-states
#19
R J Wong, M T Nguyen, H N Trinh, A Huynh, M T Ly, H A Nguyen, K K Nguyen, J Yang, R T Garcia, B Levitt, E da Silveira, R G Gish
Sofosbuvir/ledipasvir (SOF/LDV) is the first all-oral ribavirin-free treatment approved for chronic hepatitis C virus (HCV) genotype 6, offering a safe and highly efficacious treatment option. Large studies evaluating real-world outcomes of this regimen are lacking. We aim to evaluate real-world treatment outcomes for HCV genotype 6. A retrospective cohort study evaluated 65 adults (age ≥18) with chronic HCV genotype 6 treated with SOF/LDV without ribavirin at a community gastroenterology clinic in the United States from November 2014 to May 2016...
September 27, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27641984/future-landscape-of-hepatitis-c-research-basic-translational-and-clinical-perspectives
#20
REVIEW
Darius Moradpour, Arash Grakoui, Michael P Manns
With the latest all-oral interferon- and ribavirin-free regimens based on direct acting antivirals against the hepatitis C virus (HCV), sustained virological response rates of >90% are achieved, which is equivalent to cure. This has become possible for all genotypes and all subgroups of patients, including many of the most difficult-to-treat populations so far. Since a prophylactic HCV vaccine is not yet available, control of HCV infection will for the time being have to rely on the use of effective and safe antiviral treatments as well as their accessibility and affordability...
October 2016: Journal of Hepatology
keyword
keyword
89557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"